New: NCI-funded clinical trial search
Mednet Logo

Would you continue venetoclax indefinitely/until disease progression in patients treated with upfront venetoclax for TP53 mutated CLL?

Community PollStarted

Would you continue venetoclax indefinitely/until disease progression in patients treated with upfront venetoclax for TP53 mutated CLL?

69 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center
Answered on

First of all, for the del(17)(p13.1) and/or TP53 mutated CLL patients, venetoclax + obintuzumab may not be the best option based upon data from the CLL14 trial showing early PFS in this group as compared to what has been demonstrated in both up-front ibrutinib and acalabrutinib studies. However, we should all recognize that it is difficult to compare results across phase 3 studies. If I saw a patient in consultation with this question, I would follow the CLL14 regimen of stopping venetoclax at 1...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Medical Oncology · Columbia University Medical Center
Answered on

I think this is a complicated question for which we need more long-term data. There are many of us who prefer continuous BTKis in this high-risk patient population (until we have long-term data on BTKi-Ven combination). If they cannot take BTKis, venetoclax-based therapy is recommended for these patients currently as time-limited. Some of the initial studies of continuous venetoclax were conducted in multiply relapsed patients and patients with 17p deletion/TP53 mutations (Jones et al., PMID 292...

Join for free or sign in to see the full answer